c-ABL-IN-3 structure
|
Common Name | c-ABL-IN-3 | ||
---|---|---|---|---|
CAS Number | 2626934-64-1 | Molecular Weight | 376.29 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C17H11F3N4O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of c-ABL-IN-3c-ABL-IN-3 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50)[1]. |
Name | c-ABL-IN-3 |
---|
Description | c-ABL-IN-3 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50)[1]. |
---|---|
Related Catalog | |
References |
[1]. Michael J. RAWLING, et al. New compounds and methods. Patent WO2021048567A1. |
Molecular Formula | C17H11F3N4O3 |
---|---|
Molecular Weight | 376.29 |